

## PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT														
NATURE OF CONVEYANCE:	ASSIGNMENT														
CONVEYING PARTY DATA															
<table border="1"><thead><tr><th>Name</th><th>Execution Date</th></tr></thead><tbody><tr><td>Karl Schoenafinger</td><td>06/20/2008</td></tr><tr><td>Stefanie Keil</td><td>06/23/2008</td></tr><tr><td>Matthias Urmann</td><td>07/14/2008</td></tr><tr><td>Hans Matter</td><td>07/14/2008</td></tr><tr><td>Maike Glien</td><td>06/24/2008</td></tr><tr><td>Wolfgang Wendler</td><td>06/24/2008</td></tr></tbody></table>	Name	Execution Date	Karl Schoenafinger	06/20/2008	Stefanie Keil	06/23/2008	Matthias Urmann	07/14/2008	Hans Matter	07/14/2008	Maike Glien	06/24/2008	Wolfgang Wendler	06/24/2008	
Name	Execution Date														
Karl Schoenafinger	06/20/2008														
Stefanie Keil	06/23/2008														
Matthias Urmann	07/14/2008														
Hans Matter	07/14/2008														
Maike Glien	06/24/2008														
Wolfgang Wendler	06/24/2008														
RECEIVING PARTY DATA															
Name:	Sanofi-Aventis														
Street Address:	174 Avenue de France														
City:	Paris														
State/Country:	FRANCE														
Postal Code:	75013														
PROPERTY NUMBERS Total: 1															
<table border="1"><thead><tr><th>Property Type</th><th>Number</th></tr></thead><tbody><tr><td>Application Number:</td><td>12062759</td></tr></tbody></table>	Property Type	Number	Application Number:	12062759											
Property Type	Number														
Application Number:	12062759														
CORRESPONDENCE DATA															
Fax Number:	(908)231-2626														
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>															
Phone:	908-231-2387														
Email:	maribel.mendez@sanofi-aventis.com														
Correspondent Name:	Craig Bell														
Address Line 1:	Route 202-206														
Address Line 4:	Bridgewater, NEW JERSEY 08807														
ATTORNEY DOCKET NUMBER:	DE2005-065 US CNT														
NAME OF SUBMITTER:	Maribel Mendez														

CH \$40.00 12062759

PATENT

500607127

REEL: 021314 FRAME: 0098

Total Attachments: 2

source=DE2005065USCNTASSIGNMENT#page1.tif

source=DE2005065USCNTASSIGNMENT#page2.tif

**PATENT**

**REEL: 021314 FRAME: 0099**

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

I/we

- 1) Dr. Karl Schoenafinger, 63755 Alzenau, Germany
- 2) Dr. Stefanie Keil, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 3) Dr. Matthias Urmann, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 4) Dr. Hans Matter, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 5) Dr. Maike Glien, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 6) Dr. Wolfgang Wendler, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany

The inventors are citizens of Germany

hereby sell, assign, and transfer unto **sanofi-aventis**,  
a corporation organized under the laws of **France**,  
located at **174 avenue de France, 75013 Paris, France**,

the entire right, title and interest in and to my/our application for Letters Patent of  
the United States, executed concurrently herewith

Ser.-No.: **12/062,759**

filed: **April 4, 2008**

entitled: **Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their  
preparation, pharmaceutical compositions and methods for their use**

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said  
application for Letters Patent, and in and to all divisional or continuation applications that  
may be filed for United States Letters Patent for any of said inventions, and in and to all  
patents that may be granted on the foregoing applications, and I/we hereby agree, whenever  
requested, to communicate to said assignee, its successors and assigns, any facts known to  
me/us respecting said inventions, to testify in any legal proceeding, and to execute all  
applications or papers necessary to obtain and maintain proper patent protection on said  
inventions in the United States.

**Inventor(s):**

1<sup>st</sup>: Karl Schoenafinger Date: 20.6.2008

2<sup>nd</sup>: \_\_\_\_\_ Date: \_\_\_\_\_

3<sup>rd</sup>: \_\_\_\_\_ Date: \_\_\_\_\_

4<sup>th</sup>: \_\_\_\_\_ Date: \_\_\_\_\_

5<sup>th</sup>: \_\_\_\_\_ Date: \_\_\_\_\_

6<sup>th</sup>: \_\_\_\_\_ Date: \_\_\_\_\_

ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged,

I/we

- 1) Dr. Karl Schoenafinger, 63755 Alzenau, Germany
- 2) Dr. Stefanie Keil, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 3) Dr. Matthias Urmann, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 4) Dr. Hans Matter, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 5) Dr. Maïke Glien, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany
- 6) Dr. Wolfgang Wendler, c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany

The inventors are citizens of Germany

hereby sell, assign, and transfer unto **sanofi-aventis**,  
a corporation organized under the laws of **France**,  
located at **174 avenue de France, 75013 Paris, France**,

the entire right, title and interest in and to my/our application for Letters Patent of  
the United States, executed concurrently herewith

Ser.-No.: **12/062,759**

filed: **April 4, 2008**

entitled: **Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their  
preparation, pharmaceutical compositions and methods for their use**

and my/our entire right, title, and interest in and to all my/our inventions disclosed in said  
application for Letters Patent, and in and to all divisional or continuation applications that  
may be filed for United States Letters Patent for any of said inventions, and in and to all  
patents that may be granted on the foregoing applications, and I/we hereby agree, whenever  
requested, to communicate to said assignee, its successors and assigns, any facts known to  
me/us respecting said inventions, to testify in any legal proceeding, and to execute all  
applications or papers necessary to obtain and maintain proper patent protection on said  
inventions in the United States.

**Inventor(s):**

1 <sup>st</sup> :	_____	Date:	_____
2 <sup>nd</sup> :	<u>Stefanie Keil</u>	Date:	<u>23.06.2008</u>
3 <sup>rd</sup> :	<u>Matthias Urmann</u>	Date:	<u>14.7.2008</u>
4 <sup>th</sup> :	<u>Hans Matter</u>	Date:	<u>14.7.2008</u>
5 <sup>th</sup> :	<u>Maïke Glien</u>	Date:	<u>24.06.2008</u>
6 <sup>th</sup> :	<u>Wolfgang Wendler</u>	Date:	<u>24.06.2008</u>

**PATENT****RECORDED: 07/30/2008****REEL: 021314 FRAME: 0101**